INTRODUCTION
In pulmonary hypertension (PH), there is increased resistance to blood flow through the lungs, leading to elevated blood pressure in the pulmonary circulation. Pulmonary arterial hypertension (PAH) is a category of PH that refers to World Health Organization group I conditions associated with pulmonary arteriolar remodeling. In this group of diseases, vascular obstruction leads to right heart failure and, ultimately, death. Growth factors, proteases, cytokines, and aberrant bone morphogenetic protein receptor-2 (BMPR2)/metabolic signaling have been suggested to drive the obliterative changes in the small pulmonary arterioles in PAH (1) . PH can be idiopathic or associated with disorders ranging from congenital heart disease to HIV infection and connective tissue disorders (1) . At least for some patients, inflammation appears to play a major pathogenic role (2, 3) . In a preclinical animal model, dysregulated immunity resulting from deficient regulatory T cell (T reg ) activity contributes to increased inflammation in experimental PH (4) . (By convention, animal models are still referred to as having PH rather than PAH.) Macrophages, in particular, are prominent components of the inflammatory infiltrates in the lungs of patients and animals with PH (4-7). Whether activated macrophages directly promote vascular injury and the development of angio-obliterative PH is not known.
Leukotrienes (LTs) are prominent eicosanoid products of leukocytes, including macrophages, and are important mediators of inflammation (8) . Leukotriene B 4 (LTB 4 ) and the cysteinyl LTs (CysLTs) (LTC 4 , LTD 4 , and LTE 4 ) are synthesized by the enzymatic action of 5-lipoxygenase (5-LO), which acts on arachidonic acid (AA) to yield leukotriene A 4 (LTA 4 ). LTA 4 is quickly converted by leukotriene A 4 hydrolase (LTA 4 H) to LTB 4 or, alternatively, by LTC 4 synthase (LTC 4 S) to LTC 4 ( Fig. 1A) . LTC 4 can be metabolized by sequential hydrolysis to LTD 4 and LTE 4 . LT production is regulated by (i) the posttranslational activation of 5-LO by phosphorylation, (ii) 5-LO interaction with 5-LO activation protein (FLAP), (iii) 5-LO subcellular localization, and (iv) the intracellular Ca 2+ concentration (8, 9) . Phosphorylation of 5-LO by p38 mitogen-activated protein kinase (MAPK) on residue Ser 271 increases its enzyme activity in vitro. Ser 271 phosphorylation also facilitates the nuclear retention of 5-LO, which enhances LTB 4 biosynthesis (10) (11) (12) (13) (14) .
5-LO expression is elevated in pulmonary macrophages and small pulmonary artery endothelial cells (PAECs) in patients with idiopathic pulmonary arterial hypertension (iPAH) (15) . Targeted disruption of the 5-LO gene in mice and pharmacologic blockade of 5-LO function in rats attenuate chronic hypoxia-associated PH (16) . Conversely, adenovirus-mediated up-regulation of 5-LO increases the susceptibility of heterozygous BMPR2 mutant mice to PH (17) . CysLTs are elevated in neonatal PH (18) and have been studied because of their established role in smooth muscle contraction (19) . Although LTB 4 was initially recognized as a chemoattractant for neutrophils, it is now known to have much broader effects in chronic inflammation (8) . How the increased expression of 5-LO and the overproduction of LTs are involved in the development of PH remains unknown.
Here, we primarily used an animal model of PH with dysregulated immunity (the SU-treated athymic rat) to study the role of macrophage LTB 4 in disease pathogenesis to determine whether LTB 4 secreted by 1 Veterans Affairs Palo Alto Health Care System/Stanford University, Palo Alto, CA 94304, USA.
infiltrating macrophages was directly injurious to pulmonary arterial endothelium. We also tested whether LTB 4 antagonism can affect PH development and progression in vivo, and we examined human PAH lungs and blood for evidence of LTB 4 participation.
RESULTS

Activation of the LTB 4 axis in macrophages in PH
In athymic (T cell-deficient) rats, a single dose of SU5416 (SU) (10 mg/kg), a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor that targets PAECs, is sufficient to induce severe and progressive PH (table S1), even under normoxic conditions (4, 20, 21) . In these rats, macrophages accumulate around partially or fully occluded small to mid-sized pulmonary arterioles (4, 7) . Using flow cytometry analysis of peripheral blood cells, we determined that CD68 + monocytes/macrophages were the primary inflammatory cells expressing 5-LO (fig. S1, A to E) in these animals. Consistent with previous studies (15, 16) , we found increased 5-LO expression by immunohistochemistry mainly in the infiltrating periarteriolar CD68 + macrophages in the lungs (fig. S1, F to J); 5-LO expression was higher in the lung than in other solid organs ( fig. S2 ).
We next examined 5-LO metabolites in our model system. Like human cells (22) [and unlike those from mice (23) ], rat macrophages produce 10 times more LTB 4 than LTC 4 (24), and we hypothesized p5-LO (green) and CD68 (red) from (E) DMSO, (F) 1 week after SU, (G) 2 weeks after SU, and (H) 3 weeks after SU. 4′,6-Diamidino-2-phenylindole (DAPI) (blue) identifies nuclei. Differential interference contrast (DIC) highlights alveolar and vascular structures. Green arrows point to the center of occluded arterioles. Merged panels show all three stains. (I) Quantitation of the data in (E) to (H) (expressed as p5-LO + macrophages per highpower field). n = 6 per group. Scale bar, 50 mm. Kruskal-Wallis test followed by Dunn's multiple comparisons test for post hoc analyses was used. Data are means ± SEM. NS, not significant. that LTB 4 is overproduced in PH. We found that the bronchoalveolar lavage fluid (BALF) from animals with PH had significantly higher LTB 4 levels than BALF from control animals, whereas LTC 4 levels were unchanged (Fig. 1B) . Similarly, serum levels of LTB 4 , but not LTC 4 , were elevated in PH (Fig. 1C) , and whole-lung transcript levels for the highaffinity LTB 4 receptor BLT1 rose progressively during the evolution of PH, whereas those of the CysLT receptor (CysLT1) did not (Fig. 1D) . pSer 271 5-LO was localized to CD68 + macrophages and, at 2 to 3 weeks after SU treatment, to the vascular wall of the lung. The number of CD68 + macrophages with pSer 271 5-LO increased as PH evolved (Fig. 1 , E to I), as did the nuclear membrane localization of pSer 271 5-LO, indicating rising LTB 4 biosynthesis in pulmonary macrophages ( fig. S3 ). LTA 4 H, which converts LTA 4 to LTB 4 , was also found in the accumulating macrophages (Fig. 2, A to E), and lung LTA 4 H mRNA increased with PH development (Fig. 2F) . In established disease, LTA 4 H was localized within cells of the vascular wall.
To test whether macrophages near arterioles in PH lungs were activated, we did a morphometric assessment of macrophages within 150 mm of arterioles. The macrophages closest to diseased pulmonary arterioles had the highest expression of both inducible nitric oxide synthase (iNOS), which is an M1 activation marker (25) (fig. S4 , A and C), and pSer 271 5-LO (p5-LO) (Fig. 2G) ; LTA 4 H + macrophages, by distinction, were common throughout the PH lung without localization near arterioles (Fig. 2G) . Most iNOS + macrophages isolated from collagenase-digested PH lungs were also p5-LO + , indicating that these arteriole-associated macrophages were primed to produce LTB 4 ( fig. S4B ). The increased iNOS expression in infiltrating, activated M1 macrophages did not lead to a net increase lung NO release ( fig. S5 ). Because NO produced by iNOS reacts with superoxide to form peroxynitrite, we measured reactive oxygen species (ROS) and found increased oxidative stress in PH lungs ( fig. S6 ), raising the possibility that ROS contribute to arteriolar injury in PH development as a result of immune dysregulation. To evaluate the relative importance of these accumulating cells in PH development, we administered clodronatecontaining liposomes to athymic rats 1 day before SU administration and biweekly thereafter for 3 weeks. This treatment reduced blood CD68 + monocytes/macrophages by 93% and prevented PH ( fig. S7 ). These data collectively demonstrate that immune dysregulation-associated 4 H + macrophages were counted and grouped as <50 mm, 50 to 100 mm, or 100 to 150 mm from the center of the small pulmonary arterioles. n = 6 per group. Scale bar, 50 mm. Kruskal-Wallis test followed by Dunn's multiple comparisons test for post hoc analyses was used. Data are means ± SEM.
PH is macrophage-dependent and is characterized by a progressive perivascular infiltration of activated macrophages with up-regulated LTB 4 synthetic machinery. LTB 4 induction of PAEC apoptosis and human pulmonary artery smooth muscle cells proliferation and hypertrophy PAEC injury is an important early event in PH pathogenesis (20) . Therefore, we next determined whether lung macrophages could injure endothelial cells in PH lungs. We established a macrophage-PAEC coculture system that used pulmonary macrophages purified separately from the interstitial and alveolar compartments, as described (26, 27) . In contrast to interstitial macrophages from control lungs, interstitial macrophages isolated from the lungs of SU-treated athymic rats with PH induced significant endothelial cell apoptosis, as assessed by flow cytometric analysis of annexin V staining; these results were confirmed by cleaved caspase-3 staining of cultured endothelial cells (Fig. 3, A and B, and fig. S8 ).
To test whether macrophage-derived LTB 4 generation was sufficient to induce endothelial damage, we first isolated interstitial macrophages from healthy rats. Next, we transfected them with S271E 5-LO to produce a 5-LO phosphorylation mimic mutant with constitutive LTB 4 production and with S271A to produce a dephosphorylation mimic mutant with deficient LTB 4 production (10) (Fig. 1B) from PH rats. Therefore, LTB 4 generated in PH macrophages was likely sufficient to cause vascular injury. In addition, blocking BLT1, the major receptor for LTB 4 in endothelial cells (29) , with U75302 prevented LTB 4 -mediated apoptosis (Fig. 3D ). These data collectively show that lung macrophages directly induce endothelial cell apoptosis ex vivo, likely through BLT1-mediated action of macrophage-derived LTB 4 . We also tested the effects of LTB 4 on human smooth muscle cells from pulmonary arterioles by adding exogenous LTB 4 . At concentrations similar to those in PH BALF (Fig. 1B) , LTB 4 induced the proliferation and hypertrophy of these cells in a concentration-and BLT1-dependent manner (Fig. 3 , F and G).
LTB 4 induction of PAEC apoptosis through inhibition of the endothelial sphingosine kinase 1-endothelial nitric oxide synthase pathway We next sought to elucidate how LTB 4 injured endothelial cells. Because endothelial nitric oxide synthase (eNOS) is activated by sphingosine 1-phosphate (S1P) (30) and is a fundamental endothelial cell survival factor (31), we hypothesized that LTB 4 inhibited endothelial sphingosine kinase 1 (Sphk1) activity (the enzyme responsible for phosphorylating sphingosine and generating S1P) and downstream eNOS activation. We measured S1P concentrations in the culture medium of PAECs (Fig. 3E ). The results paralleled those from our apoptosis assays ( Fig. 3 and fig. S8 ); the experimental groups exhibiting endothelial cell apoptosis (macrophage coculture groups: S271E, S271A plus exogenous LTB 4 , and PAECs alone with exogenous LTB 4 ) all also exhibited low S1P levels. Moreover, exogenously added S1P rescued PAECs cocultured with S271E cells (fig. S13). Next, we assessed PAECs incubated with various macrophages for the expression and activation (phosphorylation) of Sphk1 and eNOS. PAECs incubated with macrophages isolated from SU-treated PH lungs exhibited diminished levels of Sphk1 and eNOS by Western blot ( Fig. 4A and fig. S14 , A to C). Correspondingly, production of NO, a key endothelial prosurvival molecule, by activated eNOS was reduced in PAECs cultured with macrophages from SU-treated lungs (Fig. 4B ). PAECs cultured with macrophages transfected with the S271E mutant also exhibited reduced Sphk1 and eNOS compared to PAECs cultured with macrophages transfected with only vector, wild-type 5-LO, or S271A mutant DNA (Fig. 4C) . Addition of LTB 4 to cultures with macrophages transfected with S271A reduced Sphk1 and eNOS expression, whereas addition of S1P to the culture with macrophages expressing S271E restored the levels of Sphk1 and eNOS. The overall reduction in total Sphk1 and eNOS production in PAECs likely accounted for the reduction in S1P and NO levels because the ratios between the active and total forms of both Sphk1 and eNOS did not indicate a selective inhibition of the active enzymes (fig. S14, C, F, and I). NO production was reduced when PAECs were cultured with macrophages expressing S271E or S271A cultured with exogenous LTB 4 ; S1P restored NO production in the culture with S271E-expressing macrophages (Fig. 4D) . Finally, when PAECs were cultured alone with exogenous LTB 4 , similar results were obtained (Fig. 4 , E and F).
Blocking the LTB 4 -BLT1 interaction with the BLT1 antagonist U75302 prevented PAEC apoptosis and preserved the levels of Sphk1-eNOS-NO pathway components. These data collectively demonstrate that LTB 4 (and not the CysLTs) secreted by activated macrophages induces PAEC apoptosis in a BLT1-dependent manner through inhibition of endothelial S1P synthesis and NO production.
The reversal of established PH by inhibition of LTB 4 biosynthesis or LTB 4 signaling Because (i) p5-LO + and LTA 4 H + macrophages progressively infiltrated PH lungs, (ii) macrophage depletion prevented SU-induced PH, (iii) macrophage-derived LTB 4 likely mediated injury to endothelial cells, (iv) LTB 4 induced pulmonary artery smooth muscle cell (PASMC) proliferation and hypertrophy, and (v) activated LTB 4 -secreting macrophages were contiguous with diseased arterioles, we hypothesized that inhibiting LTB 4 signaling would be beneficial as a treatment in this model of PH. Bestatin [(2S, 3R)-3-amino-2-hydroxy-4-phenylbutanoyl-L-leucine] (not a statin derivative) is a well-tolerated LTA 4 H inhibitor that blocks LTB 4 formation (32, 33) . We tested whether delayed administration (a clinically relevant therapeutic strategy) of this LTA 4 H inhibitor could reverse established PH ( fig. S15 ). In the SU/athymic rat model, echocardiographic evidence of PH was first detected between 1 and 2 weeks, and severe PH was evident by 3 weeks after SU administration. For this study, we tested three delayed intraperitoneally bestatin-dosing regimens. Therapy initiated as late as 3 weeks after SU administration was highly effective in reversing PH ( fig. S15 ). Subsequently, we initiated all studies evaluating therapies in animals with severe PH 3 weeks after SU administration and followed surviving (A to F) PAECs cultured with or without macrophages were examined for pSer 225 Sphk1, total Sphk1, pSer 1177 eNOS, and total eNOS expression by Western blot. Because of differences in antibody specificity and sensitivity, blots were developed at various exposure times to best represent the signal of interest. Densitometry of the Western blots is summarized in fig. S8 . Western blots of PAECs cultured with (A) macrophages isolated from DMSO and SU-PH athymic rat lungs, (C) transfected macrophages treated with or without LTB 4 (200 nM) or S1P (1 mM), and (E) exogenous LTB 4 (200 nM) with or without U75302 (1 mM) and with or without S1P (1 mM). NO production from culture medium in (A), (C), and (E) is summarized in (B), (D), and (F), respectively. NO levels are expressed relative to background fluorescence. n = 3 experiments per group. Data are means ± SEM. NS, not significant. animals out to week 5 when they underwent a terminal right heart catheterization. A sustained-release oral formulation of bestatin was also highly effective for reversing PH (Fig. 5A and fig. S16 ). Bestatin efficacy was dose-dependent; oral availability of bestatin was determined by pharmacokinetic analysis with four different doses. Bestatin was absorbed rapidly within 3 hours and was eliminated from the body with a t 1/2 of 12 hours ( fig. S17 ). An inhalable formulation of bestatin also reversed established PH ( fig. S18 ).
Because bestatin can exert pharmacologic actions in addition to LTA 4 H inhibition (34), we sought additional evidence that reducing LTB 4 synthesis or actions was responsible for reversing PH. To this end, we tested a structurally different LTA 4 H inhibitor (JNJ-26993135) (<100 mm in external diameter) from rats described in (A). Data are expressed as % total occlusion. (E) Representative immunofluorescence images of pulmonary arterioles stained for a-SMA (red) and von Willebrand factor (vWF) (green) in lung tissues at week 5 from rats described in (A). DAPI (blue), nuclei. (F) Proportion of nonmuscularized (N), partially muscularized (P), or fully muscularized (M) pulmonary arteries, as a percentage of the total pulmonary arteriolar cross-sectional area (sized <100 mm) from rats described in (A). (G) LTB 4 , LTC 4 , and LXA 4 in BALF as measured by LC-MS/MS in rats described in (A). SU data were pooled from contemporaneous control data (n = 15) as comparator because only one of the SU (PH) rat survived to 5 weeks in this experiment, as reflected in survival curve in (B). n = 6 per group. Two-way analysis of variance (ANOVA) with Bonferroni multiple comparisons test for post hoc analyses was used. Data are means ± SEM. NS, not significant. ‡ , LXA 4 levels in the experiment groups were below the level of detection. and a BLT1 receptor antagonist (LY293111). These other two agents also reversed PH and prevented PH-related death; the CysLT antagonist montelukast had little effect (Fig. 5, A and B) . Blocking LTB 4 , either through inhibition of its biosynthesis or through receptor antagonism, increased the numbers of open arterioles and decreased arteriolar wall thickness and muscularization in parallel with reduced BALF LTB 4 levels; by contrast, antagonizing CysLTs was not effective (Fig. 5, C and F). BLT1 antagonism also induced reduced BALF LTB 4 levels, despite not blocking LTB 4 biosynthesis, suggesting an autocrine loop. In addition to blocking LTB 4 synthesis, LTA 4 H inhibition can also augment synthesis of anti-inflammatory lipoxin A 4 (LXA 4 ), and this mechanism has been suggested to contribute to decreased allergic airway inflammation (35); however, LXA 4 was undetectable in the BALF in all groups (Fig. 5G) . Furthermore, interruption of other eicosanoid pathways had little or no capacity to reverse PH. Inhibition of upstream 5-LO (with Zileuton) and FLAP (with MK886) mildly attenuated pressures and prevented death, whereas inhibition of phospholipase A 2 (PLA 2 ) (with arachidonyl trifluoromethyl ketone), cyclooxygenase (COX) (with aspirin), and epoxyeicosatrienoic acids (EETs) [with dicyclohexyl urea (DCU)] had minimal effects (Fig. 6 and fig. S19 ). (The dosing regimens for these compounds are listed in table S2.)
Next, we evaluated the anti-inflammatory effect of LTA 4 H inhibition with bestatin. Athymic SU-treated rats show vascular infiltration with macrophages and B cells during PH development (4, 7). Bestatin significantly reduced the accumulation of LTA 4 H-expressing periarteriolar macrophages, B cells, and inflammatory cytokines in the lungs of SU-treated athymic rats (figs. S20 and S21). Bestatin reduced in vivo PAEC apoptosis, possibly by suppressing LTB 4 -mediated inhibition of the Sphk1-eNOS pathway (figs. S22 to S24). To investigate whether bestatin-induced regression of vascular pathology was associated with increased apoptosis in the thickened vessel wall, we examined lungs from 4-week rats (−1 week into bestatin therapy) with histology and found them to exhibit increased terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) positivity in both the abnormal smooth muscle and intimal layers of diseased arterioles ( fig. S25 ), indicating increased apoptosis.
Finally, we tested delayed bestatin therapy in the monocrotaline (MCT) and SU/chronic hypoxia PH models. Bestatin reversed PH in wild-type rats given MCT at the same time that it reduced serum LTB 4 levels ( fig. S26 ). In contrast, SU/chronic hypoxia rats exhibited markedly fewer LTA 4 H + periarteriolar macrophages than athymic, SU-treated animals and no elevation in lung LTB 4 ; the PH of these rats failed to respond to bestatin ( fig. S27) . Thus, LTB 4 and LTB 4 -targeted therapy seems to be relevant only to experimental PH associated with immune dysregulation and characterized by high LTB 4 production.
Increased LTB 4 biosynthesis seen in human PAH
To determine the clinical relevance of the elevated LTB 4 production observed in the athymic and MCT rat models, we examined the lungs of six PAH patients for LTA 4 H expression in CD68 + macrophages. In five of six PAH lungs, LTA 4 H expression was notably increased in macrophages clustered around occluded vascular lumens of plexiform lesions (representative images from three PAH patients and a healthy control are shown in Fig. 7, A to D) . We also saw, as in the SU-treated, athymic rat, increased LTA 4 H in endothelial cells lining the nearly occluded vascular lumens of the plexiform lesions; in the sixth patient, who did not have increased LTA 4 H + pulmonary macrophages, we still observed focal increases in LTA 4 H expression in the occluded vascular lumen. Next, we assessed LTB 4 serum levels in 19 PAH patients and compared these values to those from 6 healthy individuals (Fig. 7E) . LTB 4 levels were elevated significantly in PAH patients, especially in those with connective tissue disorders; these latter individuals exhibited mean LTB 4 levels about fivefold higher than those in healthy controls. By distinction, six of eight iPAH patients appeared to have normal LTB 4 levels. There was no correlation between age and serum LTB 4 in this cohort (r 2 = 0.08). In conclusion, some, but not all, PAH patients exhibited 
DISCUSSION
Here, we report increased LTA 4 H-expressing macrophages in human PH and establish, in a rat model of immune-dysregulated PAH, that increased synthesis of macrophage-derived LTB 4 is sufficient to induce PAEC apoptosis. We further demonstrate that inhibiting LTB 4 , through LTA 4 H blockade or BLT1 antagonism, reverses the pulmonary vascular disease even after PH is already advanced. SU-mediated vascular injury in animals with dysregulated immunity leads to LTB 4 -mediated propagation of the vascular injury and results in angio-obliterative PH (Fig. 8) . Experimental evidence suggests that when an individual has an impaired ability to resolve inflammation, vascular injury progresses and results in PAH (2-4). Previous observations that T cell-deficient athymic rats develop particularly aggressive PH (4, 7, 36) can be explained by the lack of CD4 + T reg populations in these animals; these T regs , when present, are sufficient to self-limit vascular inflammation (4). Patients with conditions in which PAH occurs, such as HIV infection, systemic lupus erythematosus, systemic sclerosis, Hashimoto's thyroiditis, Sjögren's syndrome, and the antiphospholipid antibody syndrome, all exhibit abnormalities in CD4 + T cell number and function (37) (38) (39) (40) (41) (42) . A failure of T regs to resolve vascular inflammation after endothelial injury may result in the accumulation of dysregulated macrophages; overproduction of LTB 4 by these cells appears to play a key role in the evolution of PH.
Macrophages are prominent in the inflammatory infiltrate of plexiform lesions in PH (5, 6, 15) , and our data now show that macrophages, isolated from diseased lungs, can induce apoptosis of endothelial cells from pulmonary vessels. Activated iNOS + p5-LO + macrophages are concentrated close to arterioles in rat PH lungs, a finding indicating that LTB 4 -producing cells are found close to the site of disease. Increased iNOS expression in infiltrating macrophages did not correlate with increased lung NO release in SU-induced PH (lung NO liberation was generally decreased in PH lung from these animals). Decreased NO in endothelial cells can promote smooth muscle cell growth (43) . Because NO produced by iNOS reacts with superoxide to form peroxynitrite that can also damage endothelial cells (44), we assessed ROS and determined that there was indeed globally increased oxidative stress in the lungs of PH rats. However, in vitro experiments showed that antioxidant NAC treatment did not inhibit macrophage-derived LTB 4 from inducing PAEC apoptosis. Because in vitro experiments showed that culture of PAECs with exogenous LTB 4 at concentrations similar to those found in the PH BALF was also + macrophages; white arrows, occluded arterioles. Scale bars, 50 mm. (E and F) Serum LTB 4 concentrations in healthy controls (n = 6) and treatment-naïve PAH patients (n = 19). Gray shaded area in chart indicates CTD-APAH patients. (Right) Data from chart presented as concentrations (points) and means ± SEM in figure (lines and whiskers). P value reflects nonparametric one-way ANOVA with the Kruskal-Wallis test. H, Hispanic; C, Caucasian; A, Asian; AA, African American. Diagnosis: iPAH, idiopathic PAH; MCTDz-APAH, mixed connective tissue disease-associated PAH; SLE-APAH, systemic lupus erythematosus-associated PAH; Sscl-APAH, systemic sclerosis-associated PAH; NYHA, New York Heart Association functional class. WHO, World Health Organization; NTproBNP, N-terminal pro-B-type natriuretic peptide. We also demonstrate that LTB 4 , secreted by activated macrophages, induces apoptosis by ligating its cognate high-affinity heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptor, BLT1, on PAECs. Transfected pulmonary macrophages that express activated p5-LO and secrete high levels of LTB 4 effectively induce endothelial cell apoptosis, whereas transfected macrophages that secrete less LTB 4 do not. Macrophages also directly contribute to endothelial cell death in the vascular regression that occurs in normal fetal development (45) and in the plaque disruption complicating coronary artery disease (46) . Because BALF levels of LTB 4 were high and because transfected macrophages that produce abundant LTB 4 caused PAEC apoptosis, we conclude that LTB 4 is likely responsible for lung vascular injury in our athymic PH animals. The fact that macrophage depletion prevented SU-induced PH in athymic rats is consistent with the notion that macrophage-derived LTB 4 contributes to the pathogenesis of this form of experimental PH. Macrophages have been similarly implicated in models of hypoxia-induced PH (47) and the hepatopulmonary syndrome (48) . The difficulty in replicating clinical pathology of PH in mice compared to rats may in part reflect the fact that mouse macrophages produce much less LTB 4 and relatively more CysLTs (23) than do macrophages from rats (24) or humans (22) . LTB 4 is well established as an enhancer of vascular permeability (49, 50) , and its abundance in human atherosclerotic lesions correlates with symptoms of plaque instability (51) . To explain our findings that LTB 4 induces endothelial apoptosis, we evaluated a pathway used by vasoprotective prostaglandins, namely, Sphk1 and downstream eNOS (30, 52) . Recent studies on S1P have demonstrated that this bioactive sphingolipid is an important negative regulator of vascular permeability in vivo (53) , as well as an enhancer of endothelial survival mediated through eNOS and prostacyclin (30) . We show that LTB 4 induces PAEC apoptosis by inhibiting the expression of both Sphk1 and eNOS and that LTB 4 induces PASMC proliferation and hypertrophy in a dose-and BLT1-dependent manner. The thickening of the PASMC layer in PH is likely from excess augmentation of proliferation, hypertrophy, migration, as well as depressed apoptosis (54) (55) (56) (57) (58) (59) . These results with LTB 4 are consistent with the established effects of LTB 4 on other types of vascular smooth muscle cells. For example, LTB 4 has been implicated in atherogenesis, and BLT1 expression is increased in atherosclerotic plaques and on smooth muscle cells under inflammatory stress (29, 60) . LTB 4 induces signaling through nuclear factor kB (NF-kB)-dependent BLT1 receptors on coronary smooth muscle cells and causes increased proliferation and migration (29) . LTB 4 effects on PAECs and PASMCs are opposite to those induced by normal BMP signaling, which promotes PAEC health and suppresses aberrant PASMC growth (61, 62) .
R E S E A R C H A R T I C L E
We show that blocking LTB 4 action with two chemically distinct LTA 4 H inhibitors or with a BLT1 antagonist is an effective treatment for PH in immune-dysregulated rats. Bestatin therapy was also effective in the MCT rat model, results reminiscent of those of a previous study in which a BLT1 blocker reversed disease (63) . Lung histology in our treated athymic animals revealed the opening of obliterated pulmonary arterioles as well as a decrease in the number of LTA 4 H + macrophages, which otherwise rim the diseased arterioles. Bestatin therapy induced apoptosis in the smooth muscle and intimal layers of these vessels. Whether it was the antiproliferative effects of bestatin [which makes it useful as a chemotherapy adjuvant (64)] or its ability to limit LTB 4 -mediated PAEC apoptosis and PASMC proliferation/hypertrophy, the net effect of bestatin therapy was to reverse vessel remodeling.
In most of the human lungs that we examined, plexiform lesions exhibited pronounced infiltration of LTA 4 H + macrophages around occluded arterioles. In both human lungs and animals, aberrant lumen- 4 released by p5-LO-abundant macrophages and its uptake and subsequent hydrolysis by LTA 4 H-expressing PAECs. Therefore, as disease advances, LTB 4 can be generated by macrophages acting both alone and with the cooperation of aberrant PAECs. Increased PAEC expression of 5-LO has been observed in iPAH, and these abnormal intimal cells could also serve as a source of LTA 4 (15) .
Serum levels of LTB 4 were significantly elevated in PAH patients, especially in those with connective tissue disease-associated PAH (CTD-PAH). The half-life of LTB 4 is only several minutes (66) , and it is unknown how well serum LTB 4 approximates lung LTB 4 levels. In a smaller cohort of PAH patients, lung LTB 4 levels were not significantly increased, although a trend toward increased LTB 4 was seen in secondary PAH patients, a group that presumably included CTD-PAH patients (67) . Dysregulated lung macrophages may be an important source of systemic LTB 4 in these CTD patients. For example, CTD conditions associated with PAH, such as lupus and systemic sclerosis, exhibit defective T reg function (39, 68) , which may facilitate the inappropriate activation of macrophages in these conditions (69, 70) . This decrease in pulmonary T regs also characterizes iPAH (71), another disease with clear autoimmune features (72) and activated pulmonary macrophages (15) exhibiting potentially aberrant function (73) . Our results also show that macrophage-rich pulmonary inflammation and elevated systemic LTB 4 levels do not occur in all PAH patients. Similarly, the SU/chronic hypoxia model of PH does not exhibit the same degree of macrophage infiltration, high LTB 4 levels, and responsiveness to anti-LTB 4 therapy as athymic rats. Collectively, these findings are consistent with the hypothesis that different forms of PH have distinct etiologies. It should be possible to delineate and interpret preclinical PH animal models based on their comparison to human disease subtypes.
Although we show that LTA 4 H inhibition abrogates endothelial injury, the mechanisms by which this therapy actually reverses established PH may involve other LTB 4 -relevant pathways not examined here. For example, LTB 4 also causes myoblast proliferation (74) and, acting on vascular smooth muscle cells through BLT1 receptors, induces smooth muscle cell chemotaxis and proliferation in the intimal hyperplasia of atherosclerosis (29) . Additionally, LTA 4 H antagonism can attenuate inflammation in experimental allergic airway disease (35), a phenomenon possibly attributable to increased LXA 4 , an important controller of inflammation in this condition (75) . LTA 4 H is also a target for cancer prevention and therapy, and LTA 4 H inhibitors have been useful in malignancies associated with chronic inflammation (76) . The proliferation of endothelial cells in PH has been described by some investigators as having a quasi-malignant character (77, 78) . Therefore, in addition to blocking endothelial apoptosis, inhibiting LTB 4 biosynthesis may help reverse established PH by inducing apoptosis of the remodeled vascular wall, blocking disordered VEGF-mediated angiogenesis, reducing smooth muscle hyperplasia, dampening perivascular inflammation, and inhibiting abnormal endothelial cell proliferation.
Macrophage-derived LTB 4 leads to endothelial cell death and appears to contribute to the development of immune dysregulationassociated PH. The effectiveness of LTA 4 H inhibition in reducing macrophage infiltration and reversing established disease likely involves the prevention of LTB 4 biosynthesis by macrophages; LTB 4 is itself a promoter of pulmonary macrophage infiltration (79) . The ability of LTA 4 H inhibitors and a BLT1 receptor blocker to reverse severe PH supports the hypothesis that reducing LTB 4 signaling has broader action than merely acting as an anti-inflammatory agent because these therapies also appear to promote the reopening of obliterated lung vessels. Bestatin also has antitumor activity and has been used in chemotherapy regimens in leukemia (80) and as a well-tolerated adjuvant therapy in stage I lung cancer (81) . Therefore, clinical use of bestatin for the treatment of PH is possible. In keeping with the evolving concept of precision medicine, LTB 4 antagonism may be a highly effective therapy for a subset of PH patients with concomitant immune dysregulation; in such patients, LTB 4 levels in the blood or breath could serve as a useful biomarker predicting responsiveness to therapy.
MATERIALS AND METHODS
Study design
We mainly used an animal model of PH with dysregulated immunity (the SU-treated athymic rat) to study the role of macrophage LTB 4 in disease pathogenesis to determine whether LTB 4 secreted by infiltrating macrophages was directly injurious to pulmonary arterial endothelium. We used cocultures of macrophages from PH lungs and PEACs, some of which were engineered to mimic specific 5-LO phosphorylation states.
Effects of LTB 4 were tested in the MCT and SU/hypoxia models of rat PH. We also studied how LTB 4 inhibition altered PH development and progression in vivo, and we examined human PAH lungs and serum for evidence of this LTB 4 involvement. Animals were randomly assigned to experimental groups based on the weight at the time of SU or vehicle treatment. All experiments were repeated at least three times.
Animal model
The experimental protocol was approved by the Veterans Affairs Palo Alto Animal Care and Use Committee. Athymic nude rats (rnu/rnu; Charles River Laboratories) were used for these studies. Six-to 8-weekold animals were injected subcutaneously with a single dose of either SU (10 mg/kg) dissolved in DMSO or DMSO (vehicle) alone. All animals were maintained under normoxic conditions. Bestatin was injected intraperitoneally or given by inhalation three times per week starting at the time of SU administration or 1, 2, or 3 weeks after SU administration. Oral bestatin, JNJ-26993135, and other eicosanoid inhibitors were administered daily 3 weeks after SU injection. Detailed dosing regimen is listed in table S2. 
BALF preparation
The rats were euthanized. A tracheal cannula was inserted, and the lung was lavaged with ice-cold Ca 2+ /Mg 2+ -free phosphate-buffered saline (PBS) at a volume of 6 ml for the first lavage and 8 ml for subsequent lavages. BALF samples were centrifuged at 500g for 10 min at 4°C to pellet the cells. Supernatants were collected for LC-MS/MS assay.
Isolation of interstitial macrophages
Isolation of interstitial macrophagess was performed according to published methods (82) . After exhaustive lung lavage (~30 times), the pulmonary artery was cannulated and the left atrium was opened. The lung vascular bed was perfused with ice-cold PBS-EDTA until the tissue turned white; this step was followed by perfusion with RPMI 1640 containing deoxyribonuclease (66 U/ml) and collagenase (50 U/ml). Lungs were then excised, and the tissues were sliced into 0.4-mm pieces. The lung tissue fragments were incubated with RPMI 1640 containing collagenase (50 U/ml) and 10% fetal calf serum (FCS) for 60 min at 37°C in a gently shaking water bath. The lung-digested cells were then washed and layered on top of a two-step Percoll gradient (20 to 50%). After centrifugation at 300g, the interphase between the 20 and 50% Percoll layers was harvested, washed again, and resuspended in RPMI 1640 with 10% FCS. To further enrich the isolated cells for macrophages, we seeded cells on petri dishes and washed them carefully after 5 hours of incubation period. The remaining cells were >95% macrophages as determined by flow cytometry.
Isolation of alveolar macrophages in BALF Rats were euthanized. A tracheal cannula was inserted, and the lung was lavaged with ice-cold Ca 2+ /Mg 2+ -free PBS at a volume of 6 ml for 18 times. The alveolar macrophages were retrieved from the lavage effluents by centrifuging at 300g for 10 min. The cells were washed twice and resuspended to 1 × 10 6 cells/ml in RPMI 1640 with 10% FCS and plated on petri dishes. Five hours after attaching, the remaining cells were >95% macrophages as determined by flow cytometry.
Transfection of macrophages
Eight hours after attaching, macrophages were trypsinized from the petri dish and resuspended to a concentration of 1 × 10 6 /ml of transfection solution. Five micrograms of pEGFP-C1 vector (a gift from W. Cho, University of Illinois at Chicago), wild-type 5-LO, S271E, or S271A DNA was added to 100 ml of each of the macrophage suspensions. Mixtures were loaded into the cuvette, followed by preprogrammed transfection with 3D Nucleofactor (Lonza). Transfection efficiency was determined the next day with flow cytometry gated on the EGFP (enhanced green fluorescent protein) channel.
Determination of medial wall thickness
Frozen sections of the lung were fixed and blocked with 10% donkey serum in PBS with 1% bovine serum albumin. The tissue sections were then incubated with anti-SMA (Abcam) primary antibody and biotinylated donkey anti-rabbit secondary antibodies (Santa Cruz Biotechnology) followed by hematoxylin staining. The percentage of wall thickness was determined as described (83) and was as follows: % wall thickness = (WT1 + WT2)/(external diameter of vessel) × 100, where WT1 and WT2 refer to wall thicknesses measured at two points diametrically opposite to each other. The endothelial component of the vessel wall was excluded from the measurements of wall thickness.
Degree of muscularization
To determine the degree of muscularization, we identified vessels <100 mm with positive a-SMA cell staining surrounding endothelial cells and classified them as follows: none, partially muscularized, or fully muscularized. The degree of muscularization was expressed as % ratio of number of vessels to the number of total vessels.
PAEC apoptosis assay
Rat PAECs were cocultured with macrophages (+/− transfection) for 24 hours. They were then washed once with PBS and once with binding buffer from the Annexin V Apoptosis Detection Kit (88-8007; eBioscience). Cells were then suspended in binding buffer at 1 × 10 6 to 5 × 10 6 /ml. Allophycocyanin-conjugated annexin V (5 ml) was added to 100 ml of cells and incubated at room temperature for 15 min. Propidium iodide staining solution (5 ml) was added 5 min before flow cytometry analysis on the LSRFortessa cell analyzer (BD Biosciences). Serum starvation for 24 hours was performed to synchronize PAEC.
hPASMC proliferation assay
In Vitro Toxicology Assay Kit, MTT based (#M-5655, #8910, Sigma) was used to measure the number of viable hPASMC after LTB 4 treatment. Briefly, hPASMCs were plated on a 96-well plate 2 days before treatment. hPASMCs were serum-starved for 24 hours before they were treated with 200 nM LTB 4 , 400 nM LTB 4 , or 200 nM LTB 4 and 1 mM U75302 for 24 hours. On the day of assay, growing medium was first removed from the cell. Twenty microliters of 12 mM MTT solution was then added to each well. The plate was incubated at 37°C for 4 hours. MTT dissolving solution (200 ml) (10% Triton X-100 plus 0.1 N HCl in anhydrous isopropanol) was then added to each well. Relative optical density used as an index for proliferation was calculated by subtracting the absorbance at 690 nm from that at 570 nm.
hPASMC hypertrophy Cellular hypertrophy was determined by calculating protein/DNA ratio. Briefly, hPASMCs were seeded on six-well plates 2 days before treatment. hPASMCs were serum-starved for 24 hours before they were treated with 200 nM LTB 4 , 400 nM LTB 4 , or 200 nM LTB 4 plus 1 mM U75302 for 24 hours. hPASMCs were then collected and divided into two. For one portion of the sample, BCA protein assay (#23227, Thermo Scientific) was used to determine the total protein amount. DNA was purified from the other part of the sample with Miniprep (Qiagen). DNA concentration was measured by NanoDrop. Protein/DNA ratio was then calculated.
NO production assay
The Nitric Oxide Synthase Detection Kit (Cell Technology Inc.) was used to detect the cellular NO production in the cocultured medium. Briefly, rat PAECs were washed with PBS once before adding 1× DAF-2DA, a cell-permeable reagent that measures free NO and NOS activity. Samples were incubated at 37°C for 60 min and read on a fluorescent plate reader at an excitation wavelength of 488 nm and emission wavelength of 515 nm.
Measurements of hemodynamics
Rats were anesthetized with ketamine hydrochloride (70 mg/kg) and xylazine (10 mg/kg) injected intraperitoneally before right heart catheterization. RVSP measurements were obtained by insertion of a on September 3, 2014 stm.sciencemag.org 
Echocardiography
Echocardiographic evaluation of RV dimensions and pulmonary hemodynamics was performed with the Vivid 7 Dimension Cardiovascular Imaging System (GE), equipped with a 14-MHz transducer. Rats were lightly sedated with isoflurane for the duration of the procedure. The chests were depilated before obtaining echocardiographies. The rats were laid supine on a warming handling platform. Pulmonary artery Doppler tracings were obtained from the pulmonary artery parasternal short-axis views. The RV free wall was imaged from a modified parasternal long-axis view. All measurements were made in the expiratory phase of the respiratory cycle.
Immunohistochemistry of human tissue
Paraffin-embedded, formalin-fixed human lung tissues from two healthy control subjects and six PAH patients were obtained from the Pulmonary Hypertension Breakthrough Initiative Tissue Bank at Stanford. ) in 1% NSS overnight at 4°C, followed by anti-rabbit Alexa Fluor 594 (1:100, Invitrogen) for 4 hours at room temperature. Sections were then incubated with anti-mouse CD68 (1:50, LifeSpan Biosciences) overnight at 4°C in PBS, followed by anti-mouse Alexa Fluor 488 (1:100, Invitrogen) for 4 hours at room temperature. Negative controls with isotype immunoglobulin G were run in parallel. Images were acquired by laser-scanning confocal microscopy with a Leica TCS-SP2 confocal microscope and analyzed with ImageJ.
Human serum LTB 4 measurements
The full methods are provided in the Supplementary Materials and Methods. Briefly, serum from de-identified healthy controls and patients with iPAH and CTD-APAH was procured from the Institutional Review Board-approved Stanford Pulmonary Hypertension Biobank. Serum LTB 4 was isolated with solid-phase extraction and quantified with LC-MS/MS. Serum LTB 4 levels were measured for normality with the Kolmogorov-Smirnov test, and mean values were compared across cohorts using nonparametric one-way ANOVA with the Kruskal-Wallis test. A P value of <0.05 was considered significant.
Statistics
Prism 5 (GraphPad) was used for all analyses. Values are presented as means ± SEM. The Kolmogorov-Smirnov test was used to evaluate the data for normal distribution. Differences between various groups at multiple time points were compared with two-way ANOVA, with Bonferroni multiple comparison test for post hoc analyses. For comparisons between multiple experimental groups at a single time point, Kruskal-Wallis test followed by Dunn's multiple comparisons test for post hoc analyses was used. A two-sided P value <0.05 was considered significant. S5 . In vivo NO release decreased in lungs from PH rats. Fig. S6 . Cellular ROS production is elevated in the SU group. Fig. S7 . Prevention of PH by macrophage depletion. Fig. S8 . Induction of PAEC apoptosis by interstitial lung macrophage (IMØ)-derived LTB 4 . Fig. S9 . Experimental groups of PAEC-macrophage coculture system. Fig. S10 . Induction of PAEC apoptosis by alveolar macrophage (AMØ)-derived LTB 4 . Fig. S11 . LTB 4 induction of PAEC apoptosis in a dose-dependent manner. Fig. S12 . LTB 4 induction of synchronized PAEC apoptosis in a dose-dependent manner. Fig. S13 . S1P rescues PAEC apoptosis induced by macrophage LTB 4 . Fig. S14 . Quantification of Western blots evaluating LTB 4 -mediated PAEC apoptosis. Table S1 . Hemodynamic and echocardiographic data for athymic rats at different time points after SU administration. Table S2 . Dosing regimen for different eicosanoid inhibitors.
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